Studies blood samples to find the genetic cause of juvenile myoclonic epilepsy
Collects blood samples and brain wave recordings from people with juvenile myoclonic epilepsy.
Plain-language title generated from the registry record
Registry title: Biology of Juvenile Myoclonic Epilepsy
Key facts
- Where
- Paris, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 40 years old?
Source: NCT03400371, who can take part
Where in France
- University Robert DebréParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- King's College London
- Trial code
- NCT03400371
- Record updated
- 5 September 2025
- Original description
The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to anonymised data from samples for 2000 controls. The goal of this study is to find the genetic cause of JME. Finding the cause will help create better treatments for JME, as well as improve patient outcomes by allowing us to detect it earlier.Read full original descriptionShow less
Biology of Juvenile Myoclonic Epilepsy
The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to anonymised data from samples for 2000 controls. The goal of this study is to find the genetic cause of JME. Finding the cause will help create better treatments for JME, as well as improve patient outcomes by allowing us to detect it earlier.
Inclusion: Diagnosis of Juvenile Myoclonic Epilepsy in accordance with Consensus criteria; Age of myoclonus onset 10-25 years; Seizures comprising predominant or exclusive early morning myoclonus of upper extremities; EEG interictal generalized spikes and/or polyspike and waves with normal background; Current age 10-40 years.
Exclusion: Myoclonus only associated with carbamazepine or lamotrigine therapy; Any evidence of progressive or symptomatic myoclonus epilepsy or focal seizures; Dysmorphic syndrome; EEG showing predominant focal interictal epileptiform discharges or abnormal background; Global learning disability; Unable to provide informed consent; Regrettably, we are currently unable to accept self-referrals to the BIOJUME study.